Dutch Drug Prices "25% Too High"

23 January 1995

The Dutch Minister of Health, Els Borst-Eilers, has said that pharmaceutical prices in the Netherlands are the highest in Europe, and that they are at least 25% too high. This is despite the fact that the Dutch consume far fewer medicines than other European countries, she added.

Last month, the Minister reached agreement with the Ministries of Finance and Economic Affairs for the introduction of measures aimed at saving up to 800 million guilders ($465.7 million) a year on the health care budget. These measures are reported to include an essential drugs list, drug price reductions and moves to encourage generic prescribing.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight